7 April 2026
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Notice of Results
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care will announce its results for the year ended 31 December 2025 on Monday 13 April 2026.
Enquiries:
|
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer |
Tel: 01223 810700 |
|
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks |
Tel: 020 7220 0500 Corporate Finance Corporate Broking LS Specialist Sales |
|
Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram |
Tel: 020 7496 3000 |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.
Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:
- Clinical Studies for new pharmaceuticals;
- Academic Research for scientists to understand CNS disorders;
- Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,
- Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.
For further information, visit: www.cambridgecognition.com